

Literature Review

Budesonide (IBD, Ulcerative
Colitis, Crohn's Disease)

Medication	Title of Article	Pubmedlink
BUDESONIDE	Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.	https://www.ncbi.nlm.nih.gov/pubmed/?term=274160 45
BUDESONIDE	Systemic secondary amyloidosis in a 70-year-old patient with Crohn's disease: treatment with oral budesonide.	https://www.ncbi.nlm.nih.gov/pubmed/?term=234788 07
BUDESONIDE	Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: a randomized placebo-controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=192299 88
BUDESONIDE	Oral budesonide for the therapy of post-liver transplant de novo inflammatory bowel disease: a case series and systematic review of the literature.	https://www.ncbi.nlm.nih.gov/pubmed/?term=186186 76
BUDESONIDE	Oral budesonide therapy for ulcerative colitis: a topical tale.	https://www.ncbi.nlm.nih.gov/pubmed/?term=896443 0
BUDESONIDE	Oral budesonide for induction of remission in ulcerative colitis. [Review][Update of Cochrane Database Syst Rev. 2010;(10):CD007698; PMID: 20927762]	https://www.ncbi.nlm.nih.gov/pubmed/?term=264977 19
BUDESONIDE	Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=245341 42
BUDESONIDE	Oral budesonide for induction of remission in ulcerative colitis. [Review][Update in Cochrane Database Syst Rev. 2015;10:CD007698; PMID: 26497719]	https://www.ncbi.nlm.nih.gov/pubmed/?term=209277 62
BUDESONIDE	Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=190359 72
BUDESONIDE	Oral formulations of budesonide: a novel treatment for inflammatory bowel disease. [Review] [54 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=191802 63
BUDESONIDE	Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=189268 26
BUDESONIDE	Oral budesonide therapy improves quality of life in patients with collagenous colitis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=155493 26
BUDESONIDE	Evaluation of oral budesonide in the treatment of active distal ulcerative colitis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=155102 33
BUDESONIDE	Oral budesonide in the management of Crohn's disease. [Review] [38 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=145190 35
BUDESONIDE	Oral budesonide significantly improves water absorption in patients with ileostomy for Crohn disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=127374 44

Medication	Title of Article	Pubmedlink
BUDESONIDE	Replacement of conventional glucocorticoids by oral pH-modified release budesonide in active and inactive Crohn's disease: results of an open, prospective, multicenter trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=126436 18
BUDESONIDE	A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules.	https://www.ncbi.nlm.nih.gov/pubmed/?term=126227 61
BUDESONIDE	Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn's disease in children.	https://www.ncbi.nlm.nih.gov/pubmed/?term=118157 67
BUDESONIDE	Oral budesonide approved for active Crohn's disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=117637 99
BUDESONIDE	Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group.	https://www.ncbi.nlm.nih.gov/pubmed/?term=961630 9
BUDESONIDE	Oral budesonide therapy for steroid-dependent ulcerative colitis: a pilot trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=966382 8
BUDESONIDE	Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group.	https://www.ncbi.nlm.nih.gov/pubmed/?term=930150 0
BUDESONIDE	Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.	https://www.ncbi.nlm.nih.gov/pubmed/?term=916451 7
BUDESONIDE	Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=896439 5
BUDESONIDE	Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.	https://www.ncbi.nlm.nih.gov/pubmed/?term=807852 9
BUDESONIDE	Treatment of active Crohn's disease with an oral slow-release budesonide formulation.	https://www.ncbi.nlm.nih.gov/pubmed/?term=850340 3
BUDESONIDE	Oral budesonide in active Crohn's disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=816166 6